Serina Therapeutics posts FY 2024 net loss of $11.1M vs net income of $5.3M in 2023

Serina Therapeutics, Inc.

Revenues fell to $56K from $3.2M; operating expenses rose to $17.1M from $6.3M.
Cash and equivalents $3.7M at Dec 31, 2024; plus $5M from JuvVentures in Jan 2025, projected to fund through Q2 2025.
R&D expense increased $5.1M to $7.5M, driven by SER-252 development and higher headcount.
Sold UniverXome subsidiary in Dec 2024, eliminating $11.2M debt; $10M equity financing from JuvVentures secured.
Appointed Karen J. Wilson and Dr. Jay Venkatesan to board; targeting first patient in Phase 1b trial for SER-252 in Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.